KY 0301
Alternative Names: KY-0301Latest Information Update: 24 May 2024
At a glance
- Originator Novatim Immune Therapeutics (Zhejiang)
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Epidermal growth factor modulators; Proto-oncogene protein c-met modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 08 Apr 2024 Preclinical trials in Solid tumours in USA and China (Parenteral) (Novatim Immune Therapeutics pipeline, April 2024)